All requests should be submitted by a medically qualified physician. Kura Oncology is committed to providing a fair and equitable evaluation of all the requests we receive. Therefore, all decisions are based on clinical circumstances. Whenever possible, patients will be referred to ongoing clinical trials as the primary way to access investigational drugs. We will review requests on a case by case basis, and the fact that our treatment is made available to one patient, does not guarantee it will be made available to future patients. We continually evaluate the benefit-risk profile of our investigational drugs, and, based on evolving clinical data, we may require additional information from a treating physician in order to fully evaluate a request. We cannot guarantee that all requests for access will be granted, even when eligibility criteria are met. Physicians seeking pre-approval access to a Kura Oncology investigational drug should submit their requests below. We regularly monitor the mailbox that these requests may be submitted to and we will acknowledge each submitted request within one business day after receipt. You can find further contact details on the Contact Us page of our website.